Basile, V.; Puglisi, S.; Altieri, B.; Canu, L.; Libè, R.; Ceccato, F.; Beuschlein, F.; Quinkler, M.; Calabrese, A.; Perotti, P.;
et al. What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question. J. Pers. Med. 2021, 11, 269.
https://doi.org/10.3390/jpm11040269
AMA Style
Basile V, Puglisi S, Altieri B, Canu L, Libè R, Ceccato F, Beuschlein F, Quinkler M, Calabrese A, Perotti P,
et al. What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question. Journal of Personalized Medicine. 2021; 11(4):269.
https://doi.org/10.3390/jpm11040269
Chicago/Turabian Style
Basile, Vittoria, Soraya Puglisi, Barbara Altieri, Letizia Canu, Rossella Libè, Filippo Ceccato, Felix Beuschlein, Marcus Quinkler, Anna Calabrese, Paola Perotti,
and et al. 2021. "What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question" Journal of Personalized Medicine 11, no. 4: 269.
https://doi.org/10.3390/jpm11040269
APA Style
Basile, V., Puglisi, S., Altieri, B., Canu, L., Libè, R., Ceccato, F., Beuschlein, F., Quinkler, M., Calabrese, A., Perotti, P., Berchialla, P., Dischinger, U., Megerle, F., Baudin, E., Bourdeau, I., Lacroix, A., Loli, P., Berruti, A., Kastelan, D.,
... Terzolo, M.
(2021). What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question. Journal of Personalized Medicine, 11(4), 269.
https://doi.org/10.3390/jpm11040269